CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $3.18B, above the global median of $1.18B
- PositionReturn on equity is 36.3%, higher than 95% of its Medical Devices peers (median 3.7%)
- Interpretations6 currently firing — 6
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.18BUSDvs all stocks (USD)
Trailing P/E
23.23xvs Medical Devices peers
Revenue (TTM)
668.47MUSDvs all stocks (USD)
Profit Margin
22.69%vs Medical Devices peers
Beta
1.88xvs all stocks
52-Week Change
-22.29%vs all stocks
Market Capitalization
3.18BUSDvs all stocks (USD)
Enterprise Value
3.58BUSDvs all stocks (USD)
Trailing P/E
23.23xvs Medical Devices peers
Forward P/E
38.89xvs Medical Devices peers
PEG Ratio
-0.3922xvs Medical Devices peers
Price to Sales (TTM)
4.65xvs Medical Devices peers
Price to Book (MRQ)
5.99xvs Medical Devices peers
Enterprise to Revenue
5.35xvs Medical Devices peers
Enterprise to EBITDA
30.93xvs Medical Devices peers
Gross Margin
59.59%vs Medical Devices peers
Profit Margin
22.69%vs Medical Devices peers
Operating Margin
12.50%vs Medical Devices peers
Return on Assets (TTM)
4.33%vs Medical Devices peers
Return on Equity (TTM)
36.29%vs Medical Devices peers
Revenue (TTM)
668.47MUSDvs all stocks (USD)
Revenue per Share (TTM)
19.47USDUpdated Aug 28, 2026Quarterly Revenue Growth
20.70%vs Medical Devices peers
Gross Profit (TTM)
392.35MUSDvs all stocks (USD)
EBITDA (TTM)
130.22MUSDvs all stocks (USD)
Net Income (TTM)
151.70MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-57.90%vs Medical Devices peers
Operating Cash Flow (TTM)
145.93MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
44.50MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
605.49MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
242.69MUSDFY2025 · Dec 31, 2025Gross Profit
362.81MUSDFY2025 · Dec 31, 2025Operating Income
108.58MUSDvs all stocks (USD)
Pre-tax Income
107.52MUSDFY2025 · Dec 31, 2025Income Tax Expense
-82.77MUSDFY2025 · Dec 31, 2025Net Income
190.29MUSDFY2025 · Dec 31, 2025EBIT
121.30MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
148.49MUSDFY2025 · Dec 31, 2025Research & Development
69.06MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
185.17MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
13.78MUSDFY2025 · Dec 31, 2025EPS (Basic)
5.60USDFY2025 · Dec 31, 2025EPS (Diluted)
4.87USDFY2025 · Dec 31, 2025Basic Shares Outstanding
33.99MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
33.99MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
190.29MUSDFY2025 · Dec 31, 2025Operating Cash Flow
180.45MUSDFY2025 · Dec 31, 2025Free Cash Flow
121.20MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
488.87MUSDFY2025 · Dec 31, 2025Interest Paid
10.70MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
190.29MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
27.18MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-83.54MUSDFY2025 · Dec 31, 2025Stock-based Compensation
36.86MUSDFY2025 · Dec 31, 2025Other Non-cash Items
5.21MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
13.95MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-19.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-9.49MUSDFY2025 · Dec 31, 2025Capital Expenditures
-59.25MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
-59.25MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-138.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-138.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
34.63MSharesUpdated Aug 28, 2026Float Shares
33.56MSharesUpdated Aug 28, 2026Shares Short
7.91MSharesUpdated Aug 28, 2026Short Ratio
8.19daysvs all stocks
Short % of Shares Outstanding
35.52%vs all stocks
% Held by Insiders
3.64%vs all stocks
% Held by Institutions
103.26%vs all stocks
Total Cash (MRQ)
472.68MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
13.63USDUpdated Aug 28, 2026Total Debt (MRQ)
867.72MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.67xvs Medical Devices peers
Current Ratio (MRQ)
6.63xvs Medical Devices peers
Book Value per Share (MRQ)
14.96USDUpdated Aug 28, 2026Total Assets
1.07BUSDvs all stocks (USD)
Total Current Assets
637.78MUSDFY2025 · Dec 31, 2025Total Liabilities
595.27MUSDFY2025 · Dec 31, 2025Total Non-current Assets
430.59MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
505.97MUSDFY2025 · Dec 31, 2025Total Current Liabilities
89.31MUSDFY2025 · Dec 31, 2025Cash
488.37MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
488.37MUSDFY2025 · Dec 31, 2025Accounts Receivable
84.28MUSDFY2025 · Dec 31, 2025Inventory
48.88MUSDFY2025 · Dec 31, 2025Accounts Payable
10.35MUSDFY2025 · Dec 31, 2025Short-term Debt
13.31MUSDFY2025 · Dec 31, 2025Deferred Revenue
2.90MUSDFY2025 · Dec 31, 2025Long-term Debt
505.97MUSDFY2025 · Dec 31, 2025Common Stock (Book)
750.93MUSDFY2025 · Dec 31, 2025Retained Earnings
-277.95MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
473.10MUSDvs all stocks (USD)
52-Week Low
60.10USDUpdated Aug 28, 202652-Week High
156.00USDUpdated Aug 28, 202652-Week Change
-22.29%vs all stocks
Beta
1.88xvs all stocks
50-Day MA
78.93USDUpdated Aug 28, 2026200-Day MA
105.71USDUpdated Aug 28, 2026Avg 10-Day Volume
527.64KSharesUpdated Aug 28, 2026Avg 30-Day Volume
861.73KSharesUpdated Aug 28, 2026Diluted EPS (TTM)
3.86USDUpdated Aug 28, 2026Other Income / Expense
12.72MUSDFY2025 · Dec 31, 20256 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 36.3%, higher than 95% of its Medical Devices peers (median 3.7%)Significant
Return on equity: 0.36Industry median: 0.04Industry P95: 0.18Peers compared: 60.00
Structural Tensions
Significant cash reserves alongside high leverageNotable
Cash (USD): 472,675,008Total Debt (USD): 867,720,000Debt-to-Equity: 1.67
Financial Health
Altman Z-Score 4.4: safe zoneNotable
Altman Z-Score: 4.40
High structural barrier to entryNotable
Barrier to Entry: 1.07
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $3.18B, above the global median of $1.18BNotable
Market cap (USD): 3,181,444,553Global Median: 1,179,398,897.704
Revenue is $668.47M, above the global median of $534.05MNotable
Revenue (USD): 668,467,968Global Median: 534,052,387.958
Levered free cash flow is $44.5M, above the global median of $19.23MNotable
Levered free cash flow (USD): 44,496,752Global Median: 19,234,564.734
Companies that share the same coordination system — how they create, deliver, or capture value.
Celldex Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jilin Aodong Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Disc Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
MBX Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
NewAmsterdam Pharma Co. N.V.
Tier 1ProductionApproval-Gated PipelineRule
Arcutis Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tarsus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
ABL Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Betta Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hybio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Beijing InHand Networks Technology Co., Ltd.
5 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios Elevated
Qinghai Salt Lake Industry Co., Ltd.
5 interpretationsMinimal Tax and Interest DragFCF Ratios ElevatedCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios Elevated
Insource Co., Ltd.
5 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios Elevated